BWAYBrainsWay Ltd.
Price
+39%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market undecided.
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. We are dedicated to leading through superior science and building on what we believe to be an unparalleled body of clinical evidence.
In the company’s own words · 20-F filed Apr 20, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
BrainsWay Ltd. (BWAY) reported revenue of $28M in H2 2025 (quarter ended Dec 31, 2025), up 297% from the same quarter a year earlier. That came with a gross margin of 76% and net income of $4.4M (16% of revenue). For the full year FY2025, revenue was $52M (+27% year on year) and net income $7.6M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.